Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates

Mixed Effects Modeling Using Stochastic Differential Equations: Illustrated by Pharmacokinetic Data of Nicotinic Acid in Obese Zucker Rats

(2015) Jacob Leander et al.   AAPS Journal

Integrated PK-PD and agent-based modeling in oncology

(2015) Zhihui Wang et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression

(2015) Gregory A. Chang et al.   Molecular Oncology

Therapy-induced tumour secretomes promote resistance and tumour progression

(2015) Anna C. Obenauf et al.   NATURE

Adaptive stress signaling in targeted cancer therapy resistance

(2015) E Pazarentzos et al.   ONCOGENE

Treatment Analysis in a Cancer Stem Cell Context Using a Tumor Growth Model Based on Cellular Automata

(2015) Ángel Monteagudo et al.   PLoS One

Computational Modeling of Tumor Response to Drug Release from Vasculature-Bound Nanoparticles

(2015) Louis T. Curtis et al.   PLoS One

Current Status of Imaging and Emerging Techniques to Evaluate Liver Metastases From Colorectal Carcinoma

(2014) Dushyant V. Sahani et al.   ANNALS OF SURGERY

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

(2014) Ho-June Lee et al.   CANCER CELL

Bridging Population and Tissue Scale Tumor Dynamics: A New Paradigm for Understanding Differences in Tumor Growth and Metastatic Disease

(2014) Jill Gallaher et al.   CANCER RESEARCH

The paradigm of mutant p53-expressing cancer stem cells and drug resistance

(2014) Yoav Shetzer et al.   CARCINOGENESIS

Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

(2014) G. R. Oxnard et al.   CLINICAL CANCER RESEARCH

Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors

(2014) M. F. Sanmamed et al.   CLINICAL CHEMISTRY

The risk of developing a second primary cancer in melanoma patients: A comprehensive review of the literature and meta-analysis

(2014) Saverio Caini et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Evolution of acquired resistance to anti-cancer therapy

(2014) Jasmine Foo et al.   JOURNAL OF THEORETICAL BIOLOGY

Acquired resistance to TKIs in solid tumours: learning from lung cancer

(2014) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

Epigenetic mechanisms of importance for drug treatment

(2014) Maxim Ivanov et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade

(2014) Evan J Lipson et al.   Journal for ImmunoTherapy of Cancer

Drug Resistance in Cancer: An Overview

(2014) Genevieve Housman et al.   Cancers

Modeling vascularized bone regeneration within a porous biodegradable CaP scaffold loaded with growth factors

(2013) Xiaoqiang Sun et al.   BIOMATERIALS

The Dynamics of Signaling as a Pharmacological Target

(2013) Marcelo Behar et al.   CELL

Tumour heterogeneity and cancer cell plasticity

(2013) Corbin E. Meacham et al.   NATURE

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

(2013) Sarah-Jane Dawson et al.   NEW ENGLAND JOURNAL OF MEDICINE

MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

(2013) N. Wagle et al.   Cancer Discovery

Systems Modeling of Anti-apoptotic Pathways in Prostate Cancer: Psychological Stress Triggers a Synergism Pattern Switch in Drug Combination Therapy

(2013) Xiaoqiang Sun et al.   PLoS Computational Biology

Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients

(2012) L. Benesova et al.   ANALYTICAL BIOCHEMISTRY

Cytokine combination therapy prediction for bone remodeling in tissue engineering based on the intracellular signaling pathway

(2012) Xiaoqiang Sun et al.   BIOMATERIALS

Multi-scale agent-based brain cancer modeling and prediction of TKI treatment response: Incorporating EGFR signaling pathway and angiogenesis

(2012) Xiaoqiang Sun et al.   BMC BIOINFORMATICS

Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies

(2012) Hiroshi Haeno et al.   CELL

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

(2012) M. Mao et al.   CLINICAL CANCER RESEARCH

Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance

(2012) Roel H. Wilting et al.   DRUG RESISTANCE UPDATES

Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer

(2012) Jasmine Foo et al.   Journal of Thoracic Oncology

Genetic heterogeneity and cancer drug resistance

(2012) Nicholas C Turner et al.   LANCET ONCOLOGY

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

(2012) J. G. Greger et al.   MOLECULAR CANCER THERAPEUTICS

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

In silico Experimentation of Glioma Microenvironment Development and Anti-tumor Therapy

(2012) Yu Wu et al.   PLoS Computational Biology

Mathematical Modeling Predicts Synergistic Antitumor Effects of Combining a Macrophage-Based, Hypoxia-Targeted Gene Therapy with Chemotherapy

(2011) M. R. Owen et al.   CANCER RESEARCH

The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAFV600EInhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells

(2011) Ruixin Liu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prediction of Drug Response in Breast Cancer Using Integrative Experimental/Computational Modeling

(2009) H. B. Frieboes et al.   CANCER RESEARCH

The evolution of tumor metastases during clonal expansion

(2009) Hiroshi Haeno et al.   JOURNAL OF THEORETICAL BIOLOGY

Tumor-Immune Interaction, Surgical Treatment, and Cancer Recurrence in a Mathematical Model of Melanoma

(2009) Steffen Eikenberry et al.   PLoS Computational Biology

Model structure and control of bone remodeling: A theoretical study

(2008) Peter Pivonka et al.   BONE

Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib

(2008) Kazuya Taniguchi et al.   CANCER SCIENCE

Cancer Cell Metabolism: Warburg and Beyond

(2008) Peggy P. Hsu et al.   CELL

Circulating mutant DNA to assess tumor dynamics

(2008) Frank Diehl et al.   NATURE MEDICINE